Lawrence E. Heisler

CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome.

Genomic DNA functions as a universal external standard in quantitative real-time PCR.

Yeast Barcoders: a chemogenomic application of a universal donor-strain collection carrying bar-code identifiers.

Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast.

Chemical-genetic profiling of imidazo[1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells.

Quantitative phenotyping via deep barcode sequencing.

A comparative analysis of DNA barcode microarray feature size.

Genotype to phenotype: a complex problem.

Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples.

A comprehensive platform for highly multiplexed mammalian functional genetic screens.

Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell.

Compound prioritization methods increase rates of chemical probe discovery in model organisms.

Multiple means to the same end: the genetic basis of acquired stress resistance in yeast.

Identification of yeast genes that confer resistance to chitosan oligosaccharide (COS) using chemogenomics.

Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents.

Functional analysis with a barcoder yeast gene overexpression system.

Effects of the Paf1 complex and histone modifications on snoRNA 3'-end formation reveal broad and locus-specific regulation.

Miniature short hairpin RNA screens to characterize antiproliferative drugs.

CHIP-MYTH: a novel interactive proteomics method for the assessment of agonist-dependent interactions of the human β₂-adrenergic receptor.

Mapping the cellular response to small molecules using chemogenomic fitness signatures.

A genome scale overexpression screen to reveal drug activity in human cells.

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing.

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.

Genomic hallmarks of localized, non-indolent prostate cancer.

Mitochondrial mutations drive prostate cancer aggression.

The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.